The use of targeted agents in first and subsequent lines of therapy is improving outcomes in patients with mutated lung cancer progressing on standard chemotherapy, but a biomarker- or precision-guided approach is needed
Subgroup analyses from the ADRIATIC study support previous practice-changing findings
ESMO Women for Oncology Award Recipient Prof. Myung-Ju Ahn discusses gender equity in lung cancer research
First recommendations are released from the ESMO/SIOG Cancer in the Elderly Working Group
In the MARIPOSA study, a significant improvement in progression-free survival was reported in a subgroup with poor prognostic factors
Safety and efficacy data of a PD-1/IL-2 bispecific antibody fusion protein were presented at an ESMO Virtual Plenary
The tyrosine kinase inhibitor showed to prolong disease-free survival as compared to chemotherapy and clinically meaningful benefit with respect to CNS disease–free survival
Dietary regimens may alter the microbiome composition, increasing bacteria with a beneficial immunogenic effect
A study reports no significant survival benefits with the concurrent treatment with durvalumab in patients with unresectable stage III NSCLC
High rates of adverse events in the experimental setting seem to limit the potential of antibody–drug conjugates for patients with NSCLC
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.